The menopausal transition: Characteristics and management

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 17, Issue 1, 2003, Pages 33-52

  Zapantis, Gregory ^a   Santoro, Nanette ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Alternative therapy; Hot flushes; Menopausal transition; Oestradiol; Perimenopause; Synthetic hormones; Uterine bleeding

Indexed keywords

CLONIDINE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CONTRACEPTIVE AGENT; DANAZOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; FEM7 COMBI; LEVONORGESTREL; LIPID; LOW DOSE ORAL CONTRACEPTIVE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; PAROXETINE; PROGESTERONE; PROGESTERONE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; TAMOXIFEN; TIBOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VERALIPRIDE; ALPHA TOCOPHEROL; BELLERGAL; ESTRADIOL; ETHINYLESTRADIOL; FLUOXETINE; GESTAGEN; HORMONE; NORELGESTROMIN; NORETHISTERONE ACETATE; NORGESTIMATE; SERTRALINE; TRANEXAMIC ACID;

AGING; BODY MASS; BONE DENSITY; BONE MINERAL; BREAST CANCER; BREAST DISCOMFORT; BREAST TENDERNESS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DIET THERAPY; DRUG EFFECT; DRUG TOXICITY; DYSMENORRHEA; DYSPAREUNIA; HEART INFARCTION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIFESTYLE; LIPID BLOOD LEVEL; MENOPAUSAL SYNDROME; METABOLISM; MOOD; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; PREMENSTRUAL DYSPHORIC DISORDER; PSYCHOTHERAPY; REVIEW; SEXUALITY; SLEEP DISORDER; SOCIAL ASPECT; THROMBOEMBOLISM; UTERUS BLEEDING; VAGINAL DRYNESS; VASOMOTOR DISORDER; VEIN THROMBOSIS; CLIMACTERIUM; DIET; DYSPHORIA; OSTEOPOROSIS; PREMENSTRUAL SYNDROME; RISK FACTOR;

EID: 0037237381     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(02)00081-7     Document Type: Review

References (116)

1. Richardson SJ, Senikas V & Nelson JF. Follicular depletion during the menopausal transition: Evidence for accelerated loss and ultimate exhaustion. Journal of Clinical Endocrinology and Metabolism 1987; 65: 1231-1236.
2. Piette C, DeMouzon J, Bachelor A & Spira A. In-vitro fertilization: Influence of women's age on pregnancy rates. Human Reproduction 1990; 5: 56-59.
3. Ahmed-Ebbiary NA, Lenton EA & Cooke ID. Hypothalamic-pituitary ageing: Progressive increase in FSH and LH concentrations throughout the reproductive life in regularly menstruating women. Clinical Endocrinology 1994; 41: 199-206.
4. Roberts VJ, Barth S, El-Roiey A & Yen SSC. Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle. Journal of Clinical Endocrinology and Metabolism 1993; 77: 1402-1410.
5. Burger HG, Dudley EC, Hopper JL et al. Prospectively measured levels of serum follicle-stimulating hormone, oestradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. Journal of Clinical Endocrinology and Metabolism 1999; 84: 4025-4030.
6. Klein NA, Battaglia DE, Miller PB et al. Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age. Journal of Clinical Endocrinology and Metabolism 1996; 81: 1946-1951.
7. Burger HG, Cahir N, Robertson DM et al. Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clinical Endocrinology 1998; 48: 809-813.
8. Santoro N, Brown JR, Adel T & Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. Journal of Clinical Endocrinology and Metabolism 1996; 81: 1495-1501.
9. Soules MR, Sherman S, Parrott E et al. Executive summary: Stages of reproductive aging workshop (STRAW). Fertility and Sterility 2001; 76: 874-878.
10. McKinlay SM, Brambilla D & Posner J. The normal menopause transition. Maturitas 1992; 14: 103-115.
11. Mitchell ES & Woods NF. Symptom experiences of midlife women: Observations from the Seattle midlife women's health study. Maturitas 1996; 25: 1-10.
12. Dennerstein L, Dudley EC, Hopper JL et al. A prospective population-based study of menopausal symptoms. Obstetrics and Gynecology 2000; 96: 351-358.
13. Guthrie JR, Dennerstein L, Hopper JL & Burger HG. Hot flushes, menstrual status and hormone levels in a population-based sample of midlife women. Obstetrics and Gynecology 1996; 88: 437-442.
14. Overlie I, Moen MH, Holte A & Finset A. Androgens and estrogens in relation to hot flushes during the menopausal transition. Maturitas 2002; 41: 69-77.
15. Hollander LE, Freeman EW, Sammel MD et al. Sleep quality, oestradiol levels, and behavioral factors in late reproductive age women. Obstetrics and Gynecology 2001; 98: 391-397.
16. Wang M, Seippel L, Purdy H & Backstrom T. Relationship between symptom severity and steroid variation in women with pre-menstrual syndrome; Study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. Journal of Clinical Endocrinology and Metabolism 1996; 81: 1076-1082.
17. Freeman EW, Rickels K, Yonders KA et al. Venlafaxine in the treatment of pre-menstrual dysphoric disorder. Obstetrics and Gynecology 2001; 98: 737-744.
18. Stearns V, Isaacs C, Rowland J et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Annals of Oncology 2000; 11: 17-22.
19. Casper RF, Dodin S, Reid RL et al. The effect of 20 μg ethinyl oestradiol/l mg norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause 1997; 4: 139-147.
20. Audet MC, Moreau M, Koltun WD et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: A randomized controlled trial. Journal of the American Medical Association 2001; 285: 2347-2354.
21. Greendale GA, Reboussin BA, Hogan P et al. Symptom relief and side effects of post-menopausal hormones: Results from the post-menopausal estrogen/progestin interventions trial. Obstetrics and Gynecology 1998; 92: 982-988.
22. Utian WH, Shoupe D, Bachmann G et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertility and Sterility 2001; 75: 1065-1079.
23. Pickar JH, Yeh I-T, Wheeler JE et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertility and Sterility 2001; 76: 25-31.
24. Archer DF, Dorin M, Lewis V et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertility and Sterility 2001; 75: 1080-1087.
25. Lobo RA, Bush T, Carr BR et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertility and Sterility 2001; 76: 13-24.
26. Notelovitz M, Cassel D, Hille D et al. Efficacy of continuous sequential transdermal oestradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. American Journal of Obstetrics and Gynecology 2000; 182: 7-12.
27. Von Holst T & Salbach B. Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women. Maturitas 2002; 41: 231-242.
28. Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: A randomized controlled trial. Lancet 2000; 356: 2059-2063.
29. Loprinzi CL, Sloan JA, Perez EA et al. Phase III evaluation of fluoxetine for treatment of hot flashes. Journal of Clinical Oncology 2002; 20: 1578-1583.
30. Goldberg RM, Loprinzi CL, O'Fallon JR et al. Transdermal clonidine for ameliorating Tamoxifen-induced hot flashes. Journal of Clinical Oncology 1994; 12: 155-158.
31. Pandya KJ, Raubertas RF, Flynn PJ et al. Oral clonidine in post-menopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program Study. Annals of Internal Medicine 2000; 132: 788-793.
32. Edington RF & Chagnon JP. Clonidine (Dixarit) for menopausal flushing. Canadian Medical Association Journal 1980; 123: 23-26.
33. Nagamani M, Kelver ME & Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. American Journal of Obstetrics and Gynecology 1987; 156: 561-565.
34. Loprinzi CL, Michalak JC, Quella SK et al. Megestrol acetate for the prevention of hot flashes. New England Journal of Medicine 1994; 331: 347-352.
35. Paterson ME. A randomized double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles. British Journal of Obstetrics and Gynaecology 1982; 89: 464-472.
36. Aslaksen K & Frankendal B. Effect of oral medroxyprogesterone acetate on menopausal symptoms in patients with endometrial carcinoma. Acta Obstetricia et Gynecologica Scandinavica 1982; 61: 423-428.
37. Schiff I, Tulchinsky D, Cramer D & Ryan KJ. Oral medroxyprogesterone in the treatment of post-menopausal symptoms. Journal of the American Medical Association 1980; 244: 1443-1445.
38. Lobo RA, McCormick W, Singer F & Roy S. DMPA compared with conjugated estrogens for the treatment of post-menopausal women. Obstetrics and Gynecology 1984; 63: 1-5.
39. Hammar M, Christau S, Nathorst-Boos J et al. A double-blind, randomized trial comparing the effects of tibolone and continuous combined hormone replacement therapy in post-menopausal women with menopausal symptoms. British Journal of Obstetrics and Gynaecology 1998; 105: 904-911.
40. Kicovic PM, Cortes-Prieto J, Luisi M et al. Placebo-controlled cross-over study of effects of Org OD14 in menopausal women. Reproduccion 1982; 6: 81-91.
41. Vercellini P, Sacerdote P, Trespidi L et al. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: A controlled study. Fertility and Sterility 1994; 62: 938-942.
42. Stadberg E, Mattsson LA & Milsom I. Factors associated with climacteric symptoms and the use of hormone replacement therapy. Acta Obstetricia et Gynecologica Scandinavica 2000; 79: 286-292.
43. Freeman EW, Sammel MD, Grisso JA et al. Hot flashes in the late reproductive years: Risk factors for African American and Caucasian women. Journal of Women's Health and Gender-Based Medicine 2001; 10: 67-76.
44. Albertazzi P, Pansini F, Bonaccorsi G et al. The effect of dietary soy supplementation on hot flushes. Obstetrics and Gynecology 1998; 91: 6-11.
45. Quella SK, Lopinzi CL, Barton DL et al. Evaluation of soy phytestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. Journal of Clinical Oncology 2000; 18: 1068-1074.
46. Van Patten CL, Olivotto IA, Chambers GK et al. Effect of soy phytoestrogens on hot flashes in post-menopausal women with breast cancer: A randomized, controlled clinical trial. Journal of Clinical Oncology 2002; 20: 1449-1455.
47. Lebherz TB & French L. Nonhormonal treatment of the menopausal syndrome. A double-blind evaluation of an autonomic system stabilizer. Obstetrics and Gynecology 1969; 33: 795-799.
48. Barton DL, Loprinzi CL, Quella SK et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. Journal of Clinical Oncology 1998; 16: 495-500.
49. Foster S, Black cohash (Cimicifuga racemosa): A literature review. Herbalgram 1999; 45: 35-49.
50. Jacobson JS, Troxel AB, Evans J et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. Journal of Clinical Oncology 2001; 19: 2739-2745.
51. Hirata JD, Swiersz LM, Zell B et al. Does dong quai have estrogenic effects in post-menopausal women? A double-blind, placebo-controlled trial. Fertility and Sterility 1997; 68: 981-986.
52. Chenoy R, Hussain S, Tayob Y et al. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. British Medical Journal 1994; 308: 501-503.
53. Coope J, Williams S & Patterson JS. A study of the effectiveness of propranolol in menopausal hot flushes. British Journal of Obstetrics and Gynaecology 1978; 85: 472-475.
54. Cardozo L, Bachmann G, McClish D et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in post-menopausal women: Second report of the Hormones and Urogenital Therapy Committee. Obstetrics and Gynecology 1998; 92: 722-727.
55. Casper F & Petri E. Local treatment of urogenital atrophy with an oestradiol-releasing vaginal ring: A comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. International Urogynecology Journal and Pelvic Floor Dysfunction 1999; 10: 171-176.
56. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an oestradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in post-menopausal women. American Journal of Obstetrics and Gynecology 1999; 180: 1072-1079.
57. Mattsson L.-A. Clinical experience with continuous combined transdermal hormone replacement therapy. Journal für Menopause 1999; 6: 25-29.
58. Santen RJ, Pinkerton JV, Conaway M et al. Treatment of urogenital atrophy with low-dose oestradiol: Preliminary results. Menopause 2002; 9: 179-187.
59. Dennerstein L, Randolph J, Taffe J et al. Hormones, mood, sexuality, and the menopausal transition. Fertility and Sterility 2002; 77(supplement 4): S42-S48.
60. Dennerstein L, Dudley E & Burger H. Are changes in sexual functioning during the midlife years due to ageing or menopause? Fertility and Sterility 2001; 76: 456-460.
61. Dennerstein L, Lehert P, Burger H & Dudley E. Mood and the menopausal transition. Journal of Nervous and Mental Disease 1999; 187: 685-691.
62. Dennerstein L, Dudley E, Guthrie J & Barrett-Connor E. Life satisfaction, symptoms, and the menopausal transition. Medscape Womens Health 2000; 5: E4.
63. Banger M. Affective syndrome during perimenopause. Maturitas 2002; 41(supplement I): S13-S18.
64. Dennerstein L, Lehert P, Burger H & Dudley E. Factor affecting sexual functioning of women in the mid-life years. Climacteric 1999; 2: 254-262.
65. Dennerstein L, Burrows GD, Wood C & Hyman G. Hormones and sexuality: Effect of estrogen and progestogen. Obstetrics and Gynecology 1980; 56: 316-322.
66. Brambilla DJ, McKinlay SM & Johannes CB. Defining the perimenopause for application in epidemiologic investigations. American Journal of Epidemiology 1994; 140: 1091-1095.
67. Dudley EC, Hopper JL, Taffe J et al. Using longitudinal data to define the perimenopause by menstrual cycle characteristics. Climacteric 1998; i: 18-25.
68. Mitchell ES, Woods NF & Marella A. Three stages of the menopausal transition from the Seattle Midlife Women's Health Study: Toward a more precise definition. Menopause 2000; 7: 334-349.
69. Wilcox LS, Koonin LM, Pokras R et al. Hysterectomy in the United States 1988-1990. Obstetrics and Gynecology 1994; 83: 549-555.
70. Cano A, Gimeno F, Fuente T et al. The positive feedback of oestradiol on gonadotropin secretion in women with perimenopausal dysfunctional uterine bleeding. European Journal of Obstetrics, Gynecology, and Reproductive Biology 1986; 22: 353-358.
71. Fraser IS & Baird D. Blood production and ovarian secretion rates of oestradiol-17β and estrone in women with dysfunctional uterine bleeding. Journal of Clinical Endocrinology and Metabolism 1974; 39: 564-570.
72. Legan SJ & Callahan WH. Suppression of tonic luteinizing hormone secretion and norepinephrine release near the GnRH neurons by oestradiol in ovariectomized rats. Neuroendocrinology 1999; 70: 237-245.
73. LaPolt PS, Matt DW & Lu JK. Progesterone implants delay age-related declines in regular estrous cyclicity in the ovarian follicular reserve in Long-Evans rats. Biology of Reproduction 1998; 59: 197-201.
74. Seltzer VL, Benjamin F & Deutsch S. Perimenopausal bleeding patterns and pathologic findings. Journal of the American Medical Womens Association 1990; 45: 132-134.
75. Bhattacharya S, Cameron IM, Parkin DE et al. A pragmatic randomized comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology 1997; 104: 601-607.
76. Aberdeen Endometrial Ablation Trials Group. A randomized trial of endometrial ablation versus hysterectomy for the treatment of dysfunctional uterine bleeding: Outcome at four years. British Journal of Obstetrics and Gynaecology 1999; 106: 360-366.
77. Amso NN, Stabinsky SA, McFaul P et al. Uterine thermal balloon therapy for the treatment of menorrhagia: The first 300 patients from a multicentre study. International Collaborative Uterine Thermal Balloon Working Group. British Journal of Obstetrics and Gynaecology 1998; 105: 517-523.
78. Lethaby A, Irvine G & Cameron I. Cyclical progestogens for heavy menstrual bleeding (Cochrane Review). The Cochrane Library. Issue 2, Oxford: Update Software; 2002.
79. Henshaw SK. Unintended pregnancy in the United States. Family Planning Perspectives 1998; 30: 24-29. see also p. 46.
80. Gebbie AE, Glasier A & Sweeting V. Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Contraception 1995; 52: 221-222
81. Davis A, Godwin A, Lippman J et al. Triphasic norgestimate-ethinyl oestradiol for treating dysfunctional uterine bleeding. Obstetrics and Gynecology 2000; 96: 913-920.
82. Sulak P, Lippman J, Siu C et al. Clinical comparison of triphasic norgestimate/35 μg ethinyl oestradiol and monophasic norethindrone acetate/20 μg ethinyl oestradiol. Contraception 1999; 59: 161-166.
83. Hampton RM, Short M, Bieber E et al. Comparison of a novel norgestimate/ethinyl oestradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception 2001; 63: 289-295.
84. Jick H, Kaye JA, Vasilakis-Scaramozza C et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: Cohort and case-control analysis. British Medical Journal 2000; 321: 1190-1195.
85. Tanis BC, Van Der Bosch MAAJ, Kemmeren JM et al. Oral contraceptives and the risk of myocardial infarction. New England Journal of Medicine 2001; 345: 1787-1793.
86. Marchbanks PA, McDonald JA, Wilson HG et al. Oral contraceptives and the risk of breast cancer. New England Journal of Medicine 2002; 346: 2025-2032.
87. Milsom I, Sundell G & Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception 1990; 42: 497-506.
88. Ness RB, Grisso JA, Klapper J et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. American Journal of Epidemiology 2000; 152: 233-241.
89. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. New England Journal of Medicine 1987; 316: 650-655.
90. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives; A practitioner's guide to meta-analysis. Human Reproduction 1997; 12: 1851-1863.
91. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. Journal of the American Medical Association 1987; 257: 796-800.
92. Sulak PJ, Scow RD, Preece C et al. Hormone withdrawal symptoms in oral contraceptive users. Obstetrics and Gynecology 2000; 95: 261-266.
93. Den Tonkelaar I & Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999; 59: 357-362.
94. World Health Organization. Cardiovascular disease and steroid hormone contraception. Report of a WHO scientific group. WHO Technical Bulletin Series 877. Geneva: WHO, 1998.
95. ACOG Practice Bulletin, The use of hormonal contraception in women with coexisting medical conditions. No. 18, July 2000. International Journal of Gynaecology & Obstetrics 2001; 75: 93-106.
96. McKinlay SM, Bifano NL & McKinlay JB. Smoking and age at menopause in women. Annals of Internal Medicine 1985; 103: 350-356.
97. Scarselli G, Tantini C, Colafranceschi M et al. Levonorgestrel-nova-T and precancerous lesions of the endometrium. European Journal of Gynaecological Oncology 1988; 9: 284-286.
98. Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Australian and New Zealand Journal of Obstetrics and Gynaecology 1990; 30: 353-356.
99. Andersson K, Mattsson LA, Rybo G & Stadberg E. Intrauterine release of levonorgestrel - A new way of adding progestogen in hormone replacement therapy. Obstetrics and Gynecology 1992; 79: 963-967.
100. Said S, Omar K, Koetsawang S et al. A multicentered phase III comparative clinical trial of depot medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1987; 35: 591-610.
101. Berenson AB, Radecki CM & Grady JJ. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstetrics and Gynecology 2001; 98: 576-582.
102. Seifer-Klauss V, Mueller JE, Luppa P et al. Bone metabolism during the perimenopausal transition: A prospective study. Maturitas 2002; 41: 23-33.
103. Ebeling PR, Atley LM, Guthrie JR, et al. Bone turnover markers and bone density across the menopausal transition. Journal of Clinical Endocrinology and Metabolism 1996; 81: 3366-3371.
104. Gambacciani M, Spinetti A, Cappagli B et al. Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: Effects on bone mineral density and metabolism. Maturitas 1994; 19: 125-131.
105. Pasco JA, Kotowicz MA, Henry MJ et al. Oral contraceptives and bone mineral density: A population-based study. American Journal of Obstetrics and Gynecology 2000; 182: 265-269.
106. Michaelsson K, Baron JA, Farahmand BY et al. Oral-contraceptive use and risk of hip fracture: A case-control study. Lancet 1999; 353: 1481-1484.
107. Alekel DL, St. Germain A, Peteson CT et al. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. American Journal of Clinical Nutrition 2000; 72: 844-852.
108. Mei J, Yeung SS & Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in post-menopausal but not pre-menopausal women. Journal of Clinical Endocrinology and Metabolism 2001; 86: 5217-5221.
109. Greendale GA, FitzGerald G, Huang M-H et al. Dietary soy isoflavones and bone mineral density; Results from the Study of Women's Health Across the Nation. American Journal of Epidemiology 2002; 155: 746-754.
110. Blumel JF, Castelo-Branco C, Rocangliolo M et al. Changes in body mass index around menopause; A population study of Chilean woman. Menopause 2001; 8: 239-244.
111. Crawford SL & Casey VA, Avis NE & McKinlay SM. A longitudinal study of weight and the menopause transition: Results from the Massachusetts Women's Health Study. Menopause 2000; 7: 96-104.
112. Guthrie JR, Dennerstein L & Dudley EC. Weight gain and the menopause: A 5-year prospective study. Climacteric 1999; ii: 205-21.
113. Matthews KA, Abrams B, Crawford S et al. Body mass index in mid-life women: Relative influence of menopause, hormone use, and ethnicity. International Journal of Obesity 2001; 25: 863-873.
114. Luoto R, Sharrett AR, Schreiner P et al. Blood pressure and menopausal transition: The Atherosclerosis Risk in Communities study (1987-95). Journal of Hypertension 2000; 18: 27-33.
115. Do KA, Green A, Guthrie JR et al. Longitudinal study of risk factors for coronary heart disease across the menopausal transition. American Journal of Epidemiology 2000; 151: 584-593.
116. Hall G, Collins A, Csemiczky G & Landgren B-M. Lipoproteins and BMI: A comparison between women during transition to menopause and regularly menstruating healthy women. Maturitas 2002; 41: 177-185.